Mink Therapeutics (INKT) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
17 Jun, 2026Opening remarks and agenda
Meeting called to order by the CEO, with board members and key executives present.
Formal portion of the meeting initiated, confirming notice and record date for stockholders.
Corporate governance
Inspector of Elections appointed and sworn in to oversee voting and ensure impartiality.
Quorum established with proxies representing 66% of outstanding shares.
Voting procedures explained, with no additional shareholder proposals received.
Overview of voting outcomes
Election of three Class II directors for three-year terms approved.
Ratification of KPMG LLP as independent auditor for fiscal year 2026 approved.
Preliminary or final voting results to be reported on Form 8-K within four business days.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Mink Therapeutics
- Advanced iNKT cell therapy into Phase II trials, expanded platform, and maintained $9.5M cash.INKT
Q1 202615 May 2026 - Director elections, auditor ratification, and governance oversight headline the annual meeting.INKT
Proxy filing1 May 2026 - Durable clinical results, strong cash position, and major trial milestones expected in 2026.INKT
Q4 202531 Mar 2026 - Net loss narrowed, cash increased, and iNKT pipeline advanced, but funding risks remain.INKT
Q2 20241 Feb 2026 - iNKT cell therapies show promise in hard-to-treat cancers and ARDS, with pivotal trials underway.INKT
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Net loss narrowed, cash burn fell, and clinical progress continues amid funding risks.INKT
Q3 202414 Jan 2026 - Net loss narrowed and clinical pipeline advanced, supporting growth and cash runway into 2025.INKT
Q4 202425 Dec 2025 - Biotech seeks up to $150M for iNKT cell therapy R&D, with ongoing losses and dilution risks.INKT
Registration Filing16 Dec 2025 - Biotech registers 4.64M shares for resale; lead iNKT therapy in Phase 2, no proceeds to company.INKT
Registration Filing16 Dec 2025